



SOLO-2

GINECO-OV227/ENGOT-OV21



Study of **O**Laparib in **O**varian Cancer

Trial setting: **Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer**

Study Design: **A Phase III, Randomised, Double Blind, Placebo Controlled**

Sponsor(s): **AstraZeneca – GINECO Leading Group**

Final No. of patients: **295**

Timeline (first patient – trial closing): **Aug 2013- Aug 2021**

Publications: ***Lancet Oncology July 2017***

Planned publications and substudies: **14 substudies in discussion – First meeting with AZ at ASCO – Next meeting at ESMO**

